簡體|繁體
Company News
Year：
2019
15/05/2019Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index
29/04/2019Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting
12/03/2019FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively
11/01/2019The cellular growth factor project of Essex Bio-Technology Limited was honored with the second prize of National Scientific and Technology Progress Award
2018
30/10/2018Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics—Its Radioactive Bandages For The Treatment Of Non-Melanoma Skin Cancer (NMSC)
29/10/2018Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018
22/08/2018Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China
10/08/2018Group Turnover and Profit in the First Half of 2018 Increased 28.3%
24/07/2018Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd
18/07/2018Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech
13/04/2018Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Cerficate for Preservative-Free Single-Dose Tobramycin Eye Drops
10/04/2018Essex Bio-Technology appoints Dr.Xue Qi as Chief Scientific Officer for its R&D centre in USA
19/03/2018Group Profit Recorded Growth of 22.8% in 2017
06/03/2018Change of Company Logo Represents a Transformation for Essex Bio-Technology
26/02/2018Essex Bio-Technology announces investment in MeiraGTx, a biotech company developing novel gene therapy treatments
2017
22/05/2017AC Immune and Essex Bio-Technology announce research collaboration for neurodegenerative diseases and neuroinflammation
2016
07/04/2016HUMACYTE,INC.,one of the investments of the group,made research and development progress in Q1 2016
21/03/2016Group turnover and profit recorded growth of 26.2% to HK$654M & 39.4% to HK$104.9 respectively
2015
28/08/2015EssexBio and Tasly to co-develop recombinant protein drugs under Strategic Co-Operation Framework Agreement
18/03/2015Group turnover and profit recorded growth of 49.3% & 37.1% respectively
2014
07/08/2014Growth of 40.1% & 13.8% in turnover and profit respectively
15/05/2014Announcement obtaining of a health food certificate by a wholly-owned subsidiary
28/04/2014Zhuhai Essex Bio-Pharmaceutical Company Limited Bestowed the Award of Outstanding Enterprise of 2013(Guangdong Province)
17/02/2014Announcement import and service agreement with Pfizer international trading (ShangHai) LTD.
2013
31/12/2013Obtaining of a certificate of good manufacturing practices for human drugs by a wholly-owed subsidiary
2011
03/08/2011Group recorded first half growth of 53.6% & 34.4% in turnover and profit respectively
23/06/2011Essex Bio-Technology Limited successfully transferred the listing from the gem board to the main board (stock code on main board: 1061) (stock code on gem: 8151)
12/05/2011Group pharmaceutical business recorded first quarter growth of 74.3% & 44.0% in turnover and profit respectively
28/03/2011Group pharmaceutical business recorded growth of 25.4% & 58.7% in turnover and profit respectively
2010
04/11/2010Group pharmaceutical business recorded growth of 22.4% & 45.1% in turnover and profit respectively
11/08/2010Group pharmaceutical business recorded growth of 22.6% & 38.3% in turnover and profit respectively
25/03/2010Group pharmaceutical business recorded moderate growth of 25.6% in revenue

About Essex|Disclaimer|Contact Us|Site Map


Copyright(C) 2012 essexbio.com All Rights Reserved.Guangdong ICP NO.09032349-1

网上购买彩票